Skip to main content
OpenTrials
Completed

NCT Number: NCT01532830

Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine

The purpose of this pilot study is to assess feasibility and clarify the design of future study(ies) to support marketing approval of the GammaCore™ device for the treatment and/or prevention of migraine symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCSF Headache Center, San Francisco, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is between the ages of 18 and 55 years.
  • Has been previously diagnosed as suffering from migraine, in accordance with the ICHD-2 Classification criteria (2nd), with or without aura.
  • Experiences at least 2 migraines per month, but less than 15 headache days per month (over the last 3 months).
  • Has age of onset of migraine less than 50 years old.
  • Is able to give written Informed Consent

Exclusion criteria

  • Has a history of aneurysm, intracranial hemorrhage, brain tumors or significant head trauma.
  • Has a lesion (including lymphadenopathy) at the GammaCore™ treatment site.
  • Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF), coronary artery disease or recent myocardial infarction.
  • Has a history or baseline ECG that identifies the presence of a clinically significant unstable cardiac arrhythmia, second degree heart block type II, history of ventricular tachycardia or ventricular fibrillation, or known cardiac syndromes that may be associated with increased risk of sudden death in otherwise healthy people.
  • Has had a previous bilateral or right cervical vagotomy.
  • Has a clinically significant irregular heart rate or rhythm.
  • Has uncontrolled high blood pressure.
  • Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
  • Has a history of carotid endarterectomy or vascular neck surgery on the right side.
  • Has been implanted with metal cervical spine hardware or has a metallic implant near the GammaCore™ stimulation site.
  • Has a recent or repeated history of syncope.
  • Has a recent or repeated history of seizure.
  • Has a history or suspicion of narcotic abuse.
  • Takes medication for acute headaches more than 10 days per month.
  • Is pregnant, nursing, thinking of becoming pregnant in the next 3 months, or of childbearing years and is unwilling to use an accepted form of birth control.
  • Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
  • Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).
  • Is a relative of or an employee of the investigator or the clinical study site.

Treatment and study plan

n-VNS

Device

Other names: gammaCore

Primary outcomes

  1. Safety - Number of Participants With Adverse Effects

    Time frame: End of Study - 7 weeks

    The primary outcome measure for this study was the assessment of adverse events as unanticipated or anticipated.

Secondary outcomes

  1. Mean Change in Headache Pain From Baseline to 120 Minutes

    Time frame: 120 minutes

    Headache was measured on a 4 point scale where 0 = no pain, 1 = mild, 2 = moderate, 3 = severe pain at baseline (start of attack), 5, 15, 30, 45, 60, 90 and 120 minutes.

    Data presented shows the average change from baseline to 120 minutes

  2. Change in Photophobia (Visual) From Baseline to 120 Minutes

    Time frame: Base line and 120 minutes

    Presence of photophobia (yes or no) was captured at baseline and 120 minutes.

  3. Change in Phonophobia (Auditory) From Baseline to 120 Minutes

    Time frame: Baseline and 120 minutes

    Presence of phonophobia (yes or no) was captured at baseline and 120 minutes.

  4. Mean Change in Nausea From Baseline to 120 Minutes

    Time frame: Baseline 120 minutes

    Nausea was captured in the diary and measured on a 4 point scale, where 0 = no nausea, 1 = mild, 2 = moderate and 3 = severe nausea, at baseline and 120 minutes.

  5. Mean Change in Functional Disability

    Time frame: Baseline and 120 minutes

    Functional disability was captured in the diary and measured on a 4 point scale, where 0 = no disability, able to function normally and where 3 = performance of daily activities severely impaired, measured at baseline and 120 minutes.

Sponsors and collaborators

Lead sponsor

ElectroCore INC

Industry

Registry information

Official study title

Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Feb 15, 2012
Registry last updated
Jul 10, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.